(IN BRIEF) AstraZeneca is set to unveil promising data at the 65th American Society of Hematology (ASH) Annual Meeting, highlighting…
ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more…
The company received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) Broad and…
The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19…